Akari Therapeutics, Plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Akari Therapeutics, Plc (AKTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 111.10% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-13
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 95.70%.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 98.10%.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 94.10%, a 13.37% increase from fiscal 2024.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 83.00%, a 16.33% decline from fiscal 2023.
- Akari Therapeutics, Plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 99.20%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 111.10% 10-Q · filed 2026-08-13 | |||||||
| 2025-12-31 | 94.10% 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | 94.10% 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 95.30% 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | 95.70% 10-Q · filed 2026-05-19 | |||||||
| 2024-12-31 | 83.00% 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | 83.00% 10-Q · filed 2025-11-13 | 82.60% 10-Q · filed 2024-11-19 | ||||||
| 2024-06-30 | 98.00% 10-Q · filed 2025-08-13 | |||||||
| 2023-12-31 | 99.20% 10-K · filed 2025-04-15 | 98.70% 10-K · filed 2024-03-29 | ||||||
| 2023-09-30 | 99.20% 10-Q · filed 2024-11-19 | |||||||
| 2023-06-30 | 99.30% 10-Q · filed 2024-08-19 | |||||||
| 2023-03-31 | 98.10% 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 75.10% 8-K · filed 2024-09-06 | 76.10% 10-K · filed 2024-03-29 | ||||||
| 2022-10-25 | 28.10% 8-K · filed 2024-09-06 | |||||||
| 2022-06-30 | 76.90% 6-K · filed 2023-09-29 | |||||||
| 2022-03-10 | 110.00% 20-F · filed 2023-05-01 | |||||||
| 2022-01-04 | 110.00% 20-F · filed 2023-05-01 | |||||||
| 2019-12-31 | 75.40% 20-F · filed 2022-05-16 | |||||||
| 2019-06-30 | 75.40% 6-K · filed 2019-08-29 | |||||||
| 2018-06-30 | 82.23% 6-K · filed 2019-08-29 | |||||||
| 2011-03-31 | 86.00% 20-F · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |